Current partner codePEPTIDESDE
PeptideStat
Menu

Vendors

Compare pricesVendor directoryVendor reviewsDiscount codesLab tests & COAs

Research

ResearchDatabaseClinical trials

Tools

All calculatorsReconstitutionAccumulationUnit converterPeptide chemistry
Evidence dashboardStudies since 1997Updated Jul 31, 2026

OctreotideClinical Trials.

A source-linked view of every Octreotide study in the current snapshot—status, phase, enrollment, results, publications, locations and changes over time.

Total trials
75
Recruiting
29
Completed
20
Terminated
5
Results posted
13
Average enrollment
129
Countries
43
Highest phase
Phase 4

Largest indexed study

655 participants · NCT03000946 →

Developer / research origin

Novartis

Evidence summary

Activity is not efficacy.

Octreotide appears in 75 indexed studies: 29 recruiting, 20 completed and 13 with registry results posted. The highest registered development stage in this snapshot is Phase 4. These counts measure registry activity; they do not establish that Octreotide is safe or effective.

Review the design, endpoints, population, protocol changes, statistical analysis and publications before drawing conclusions.

Development history

Trial timeline.

Evidence timeline

1997—2027

199720052006200720102011201420152016201720172017201820192019201920202020

Velocity

Octreotide studies by start year

Study start year · indexed snapshot

12963019971997: 1 trials1998: 0 trials1999: 0 trials2000: 0 trials2001: 0 trials2002: 0 trials20032003: 0 trials2004: 0 trials2005: 1 trials2006: 2 trials2007: 1 trials2008: 0 trials20092009: 0 trials2010: 1 trials2011: 1 trials2012: 1 trials2013: 0 trials2014: 2 trials20152015: 1 trials2016: 3 trials2017: 3 trials2018: 2 trials2019: 4 trials2020: 2 trials20212021: 5 trials2022: 7 trials2023: 8 trials2024: 8 trials2025: 12 trials2026: 9 trials20272027: 1 trials

Development

Trials by phase

Early Phase 11
Phase 114
Phase 224
Phase 325
Phase 49

Current studies

Recruiting or active

Completed studies

Finished records

Stopped studies

Withdrawn or terminated

Showing 6 of 48 studies
Showing 6 of 20 studies

Full study index

Search Octreotide trials.

Add status, phase, condition, country, result and publication filters inside this molecule’s indexed study set.

75 matching studies

Latest publications

Follow the paper trail.

PMID 28384065 ↗Yao JC, Guthrie KA, Moran C, Strosberg JR, Kulke MH, Chan JA, LoConte N, McWilliams RR, Wolin EM, Mattar B, McDonough S, Chen H, Blanke CD, Hochster HS. Phase III Prospective Randomized Comparison Trial of Depot Octreotide Plus Interferon Alfa-2b Versus Depot Octreotide Plus Bevacizumab in Patients With Advanced Carcinoid Tumors: SWOG S0518. J Clin Oncol. 2017 May 20;35(15):1695-1703. doi: 10.1200/JCO.2016.70.4072. Epub 2017 Apr 6.Linked from NCT00569127PMID 38229199 ↗Singh S, Ferone D, Capdevila J, Chan JA, de Herder WW, Halperin D, Mailman J, Hellstrom L, Liedman H, Svedberg A, Tiberg F. Methodology of the SORENTO clinical trial: a prospective, randomised, active-controlled phase 3 trial assessing the efficacy and safety of high exposure octreotide subcutaneous depot (CAM2029) in patients with GEP-NET. Trials. 2024 Jan 16;25(1):58. doi: 10.1186/s13063-023-07834-8.Linked from NCT05050942PMID 40774695 ↗Albert NL, Tabouret E, Le Rhun E, Sahm F, Furtner J, Tonn JC, Alfano C, Silva JP, Govaerts AS, Gorlia T, Mirante O, Minniti G, Weller M, Preusser M; European Organisation for Research and Treatment of Cancer Brain Tumor Group. [177Lu]Lu-DOTATATE for Recurrent Meningioma (LUMEN-1, EORTC-2334-BTG): Study Protocol for a Randomized Phase II Trial. J Nucl Med. 2026 Jan 2;67(1):23-30. doi: 10.2967/jnumed.125.269633.Linked from NCT06326190PMID 39356039 ↗St Pierre K, Cashmore BA, Bolignano D, Zoccali C, Ruospo M, Craig JC, Strippoli GF, Mallett AJ, Green SC, Tunnicliffe DJ. Interventions for preventing the progression of autosomal dominant polycystic kidney disease. Cochrane Database Syst Rev. 2024 Oct 2;10(10):CD010294. doi: 10.1002/14651858.CD010294.pub3.Linked from NCT05281328PMID 40186126 ↗Capdevila J, Pubul V, Anido U, Walter T, Molina-Cerrillo J, Alonso-Gordoa T, Garcia-Carbonero R, San-Roman-Gil M, Llana B, Jimenez-Fonseca P, Benavent Vinuales M, Ansquer C, Baudin E, Lepage C, Del Olmo-Garcia M, Ruffinelli JC, Beron A, Haissaguerre M, Deshayes E, Taieb D, Baldari S, Sansovini M, Cingarlini S, Filice A, Panzuto F, Alvarez-Alvarez R, Lousberg L, Aboubakar Nana F, Hernando J, Garcia-Alvarez A, Garcia-Burillo A, Villacampa G, Vandamme T, Fazio N, Durand A. A Randomized clinical trial evaluating the impact on survival and quality of life of 177Lutetium[Lu]-edotreotide versus everolimus in patients with neuroendocrine tumors of the lung and thymus: the LEVEL study (GETNE T-2217). BMC Cancer. 2025 Apr 4;25(1):613. doi: 10.1186/s12885-025-13941-3.Linked from NCT05918302PMID 41719493 ↗Garcia-Carbonero R, Benavent M, Jimenez-Fonseca P, Alonso-Gordoa T, Teule A, Custodio A, Tafuto S, La Casta A, Spada F, Lopez C, Ibrahim T, Iranzo V, Garcia-Alfonso P, Gonzalez-Flores E, Villanueva Silva MJ, Grande E, Panzuto F, Crespo G, Navarro M, Castellano D, Hernando J, Morales-Herrero R, Iglesias Alvarez G, Soldevilla B, Capdevila J. Axitinib and Long-Acting Octreotide in Advanced Extrapancreatic Neuroendocrine Tumors: A Randomized, Double-Blind, Placebo-Controlled, Phase III Clinical Trial (AXINET, GETNE 1107). J Clin Oncol. 2026 Mar 20;44(9):774-786. doi: 10.1200/JCO-25-01808. Epub 2026 Feb 20.Linked from NCT01744249PMID 33152282 ↗Kunz PL. Angiogenesis inhibitors in neuroendocrine tumours: finally coming of age. Lancet Oncol. 2020 Nov;21(11):1395-1397. doi: 10.1016/S1470-2045(20)30560-X. No abstract available.Linked from NCT01744249PMID 42392118 ↗Walter T, Jann H, Ansquer C, Deshayes E, Garcia-Carbonero R, Teule A, Baum RP, Verberne HJ, Cwikla JB, Srirajaskanthan R, de Mestier L, Grana CM, Buck A, Horsch D, Pavel M, Dierickx LO, Michael M, Strosberg J, Kollar A, Jimenez-Fonseca P, Rinke A, Del Olmo-Garcia M, Flaus A, Hernando J, Kluge A, Breuninger M, Melnyk S, Zhernosekov K, Capdevila J; COMPETE Investigator Team. [177Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial. Lancet. 2026 Jul 2:S0140-6736(26)00604-5. doi: 10.1016/S0140-6736(26)00604-5. Online ahead of print.Linked from NCT03049189

Related pages

Keep researching Octreotide.

Commercial research listings, where present, are kept separate from clinical evidence and are not treatment recommendations.

Lab reportsSearch the COA ledger →Source registrySearch ClinicalTrials.gov ↗